Last updated: 07/31/2020 03:00:29

A Phase I study to assess the pharmacokinetics of GSK2798745 tablets

GSK study ID

204725

See study documents

Clinicaltrials.gov ID

NCT02925546

EudraCT ID

Not applicable

EU CT Number

Not applicable

Trial status

Study complete

Overview

Eligibility

Locations

Study documents

Results summary

Plain language summaries

Additional information

Trial overview

Official title: An Open Label, Randomized, Single Dose, Crossover study to determine the Pharmacokinetics of Three Tablet Formulations of GSK2798745 in Healthy Subjects

Trial description: GSK2798745 is being developed as a novel therapeutic intervention for the treatment of pulmonary edema associated with heart failure (HF) and is currently under investigation in the form of a compounded capsule. This is an open-label, randomized, single-dose, crossover study with the purpose to determine the pharmacokinetics (PK) of three 2.4 milligrams (mg) tablet formulations of GSK2798745 in 12 healthy subjects. The three formulations developed for this study will be micronized GSK2798745 active pharmaceutical ingredient (API) (Tablet A), micronized GSK2798745 API with sodium lauryl sulfate (SLS) and hypromellose (Tablet B), milled GSK2798745 API with SLS and hypermellose (Tablet C), and Tablet D, which will be either A/B/C based on interim PK analysis of data from the first three treatment periods.

Following a 30-day screening period, subjects will be randomized to one of the 6 treatment sequences: Treatment sequence 1: ABCD, 2=CABD, 3=ACBD, 4=BACD, 5=BCAD, 6=CBAD over three 4-day treatment periods. For treatment period 4, the best formulation based on the interim analysis data from the three treatment periods will be evaluated under fed conditions. Each treatment period will be separated by a minimum of 7 (+14)-day washout period. The total duration of participation in the study will be approximately 11 weeks including the follow-up visit.

Primary purpose:

Treatment

Trial design:

Crossover Assignment

Masking:

None (Open Label)

Allocation:

Randomized

Primary outcomes:

Area under the curve (AUC) of GSK2798745

Timeframe: Blood samples will be collected at the following time points: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 15 (Day 1), 24 and 36 (Day 2), 48 (Day 3) and 72 hours (Day 4) post dose in each of the treatment periods

Maximum plasma concentration (Cmax) of GSK2798745

Secondary outcomes:

Time to maximum observed concentration (Tmax) of GSK2798745

Elimination half-life (T1/2) of GSK2798745

AUC of GSK2798745 following a standard Food Drug Administration (FDA) high fat, high calorie meal

Cmax of GSK2798745 following a standard FDA high fat, high calorie meal

Systolic and diastolic blood pressure as a measure of safety and tolerability of GSK2798745

Timeframe: Up to 11 weeks

Pulse rate as a measure of safety and tolerability of GSK2798745

Timeframe: Up to 11 weeks

Respiratory rate as a measure of safety and tolerability of GSK2798745

Timeframe: Up to 11 weeks

Safety and tolerability of single dose of GSK2798745 as assessed by electorcardiograms (ECGs)

Timeframe: Up to 11 weeks

Safety and tolerability of single dose of GSK2798745 as assessed by hematology

Timeframe: At Baseline (Day -1)

Safety and tolerability of single dose of GSK2798745 as assessed by clinical chemistry

Timeframe: At Baseline (Day -1)

Safety and tolerability of single dose of GSK2798745 as assessed by urinalysis

Timeframe: At Baseline (Day -1)

Safety and tolerability of single dose of GSK2798745 as assessed by liver function tests (LFTs)

Timeframe: At Baseline (Day -1)

Safety and tolerability of single dose of GSK2798745 as assessed by weight assessments

Timeframe: Up to 11 weeks

Safety and tolerability of single dose of GSK2798745 as assessed by appetite assessments

Timeframe: Up to 11 weeks

Safety and tolerability of single dose of GSK2798745 as assessed by troponin measurement

Timeframe: At Baseline (Day -1) and 24 hours post dose on Day 2

Number of subjects with any adverse events (AEs) as a measure of safety and tolerability of GSK2798745

Timeframe: Up to 11 weeks

Interventions:

Drug: GSK2798745 Micronized API without SLS and hypermellose (Tablet A)

Drug: GSK2798745 Micronized API with SLS and hypermellose (Tablet B)

Drug: GSK2798745 milled API without SLS and hypermellose (Tablet C)

Enrollment:

Primary completion date:

2016-07-12

Observational study model:

Not applicable

Time perspective:

Not applicable

Clinical publications:

Navin Goyal, Anna Oughton, Linda Henderson, Rosemary Schroyer, Pete Skrdla, Dennis Sprecher. Impact of Formulation Characteristics and Food on GSK2798745 Pharmacokinetics. American College of Clinical Pharmacology - 2018 Annual Meeting. 2018;7(SI):16-17. DOI: 10.1002/cpdd.610

Medical condition

Heart failure, Congestive

Product

GSK2798745

Collaborators

Not applicable

Study date(s)

October 2016 to December 2016

Type

Interventional

Phase

Participation criteria

Sex

Female & Male

Age

18 - 75 years

Accepts healthy volunteers

Yes

Between 18 and 75 years of age inclusive, at the time of signing the informed consent
Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures

History of acute coronary syndromes including unstable angina or myocardial infarction within 6 months of screening
History of stroke or seizure disorder within 5 years of Screening

Inclusion and exclusion criteria

Inclusion criteria:

Between 18 and 75 years of age inclusive, at the time of signing the informed consent
Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
Body weight >=50 kg and body mass index within the range 18 – 32 kilogram (kg)/meter (m)^2 (inclusive)
Male or female of non-child bearing potential: A male subject with a female partner of child bearing potential is eligible to participate if he agrees to use contraception as mentioned in the protocol during the treatment period and for at least 7 days after the last dose of study treatment and refrain from donating sperm during this period A female subject is eligible to participate if she is not a woman of childbearing potential (WOCBP) as defined in the protocol.
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol

Exclusion criteria:

History of acute coronary syndromes including unstable angina or myocardial infarction within 6 months of screening
History of stroke or seizure disorder within 5 years of Screening
Active ulcer disease or gastrointestinal bleeding at the time of screening
Alanine transaminase (ALT) and bilirubin >1.5x Upper limit of normal (ULN) is acceptable if bilirubin is fractionated and direct bilirubin <35%)
Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
QT interval corrected according to Fridericia’s formula (QTcF) >450 milliseconds (msec)
History or current evidence of any serious or clinically significant gastrointestinal, renal, endocrine, neurologic, hematologic or other condition that is uncontrolled on permitted therapies or that would, in the opinion of the investigator or the Medical Monitor, make the subject unsuitable for inclusion in this study
Urinary cotinine levels indicative of current smoking or regular use of tobacco- or nicotine-containing products at time of screening (cotinine levels >200 nanogram [ng]/millimeter [mL])
History of alcohol abuse within 6 months of the study based on the following criteria: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits
History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation
Presence of hepatitis B surface antigen, positive hepatitis C antibody test result at screening or within 3 months of screening.
A positive test for human immunodeficiency virus antibody
A positive pre-study drug/alcohol screen
A screening cardiac Troponin level > ULN
Use of another investigational product in a clinical study within the following time period prior to the first administration of study medication in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
Exposure to more than 4 investigational medicinal products within 12 months prior to the first administration of study medication.
Unable to refrain from the use of prescription or non-prescription drugs (including vitamins and dietary or herbal supplements) except permitted medications listed in the protocol, within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication until completion of the follow-up visit, unless in the opinion of the Investigator and/ or sponsor the medication will not interfere with the study.

Trial location(s)

Location

Status

Location

GSK Investigational Site

Overland Park, Kansas, United States, 66211

Status

Study Complete

Study documents

Protocol

Available language(s): English

Download document(s)

Scientific result summary

Available language(s): English

Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status

Study complete

Actual primary completion date

2016-07-12

Actual study completion date

2016-07-12

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information

Not applicable

Participate in clinical trial

Access to clinical trial data by researchers

Visit website